Drug Trial Radar · NCT05706623
A Phase 1 Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function
Last checked: Nov 19, 2026Latest source record: Jul 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Jan 30, 2023
Primary completion
Apr 4, 2023
Study completion Apr 4, 2023
Sponsor
- Lead sponsor
- VectivBio AGIndustry
- Sponsor type
- Industry
- First posted
- Jan 31, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective is to assess the pharmacokinetics (PK) of apraglutide in subjects with hepatic impairment compared with matched control subjects with normal hepatic function following single subcutaneous (SC) dose administration.
Conditions
- Hepatic Impairment
Interventions
ApraglutideDrug
Single dose of apraglutide
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Curve to Infinity (AUCinf) of ApraglutideTime frame: Pre-dose Day 1; 6, 12, 24, 28, 36, 40, 48, 60, 72, 96, 120, 144, 168, 240, and 312 hours post-dose
- Area Under the Curve (AUC) From Time Zero to 168 Hours Post-dose (AUC0-168h) of ApraglutideTime frame: Pre-dose Day 1; 6, 12, 24, 28, 36, 40, 48, 60, 72, 96, 120, 144, and 168 hours post-dose
- Maximum Observed Plasma Concentration (Cmax) of ApraglutideTime frame: Pre-dose Day 1; 6, 12, 24, 28, 36, 40, 48, 60, 72, 96, 120, 144, 168, 240, and 312 hours post-dose
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
APEX
Münich, Germany
Summit Clinical Research
Bratislava, Slovakia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.